Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Otros (Other)

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

  • Martín-Broto, Javier
  • Valverde, Claudia
  • Hindi, Nadia
  • Vincenzi, Bruno
  • Martínez-Trufero, Javier
  • Grignani, Giovanni
  • Italiano, Antoine
  • Lavernia, Javier
  • Vallejo, Ana
  • Tos, Paolo Dei
  • Le Loarer, Francois
  • Gonzalez-Campora, Ricardo
  • Ramos, Rafael
  • Hernández-Jover, Diana
  • Gutiérrez, Antonio
  • Serrano, César
  • Monteagudo, María
  • Leton, Rocío
  • Robledo, Mercedes
  • Moura, David S.
  • Martín-Ruiz, Marta
  • López Guerrero, José Antonio
  • Cruz, Julia
  • Fernández-Serra, Antonio
  • Blay, Jean Yves
  • Fumagalli, Elena
  • Martínez-Marín, Virginia
Background: Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to imatinib. Underlying oncogenic mechanisms in KP-wtGIST include overexpression of HIF1α high IGFR signaling through the MAPK pathway or BRAF activating mutation, among others. As regorafenib inhibits these signaling pathways, it was hypothesized that it could be more active as upfront therapy in advanced KP-wtGIST. Methods: Adult patients with advanced KP-wtGIST after central confirmation by NGS, naïve of systemic treatment for advanced disease, were included in this international phase II trial. Eligible patients received regorafenib 160 mg per day for 21 days every 28 days. The primary endpoint was disease control rate (DCR), according to RECIST 1.1 at 12 weeks by central radiological assessment. Results: From May 2016 to October 2020, 30 patients were identified as KP-wtGIST by Sanger sequencing and 16 were confirmed by central molecular screening with NGS. Finally, 15 were enrolled and received regorafenib. The study was prematurely closed due to the low accrual worsened by COVID outbreak. The DCR at 12 weeks was 86.7% by central assessment. A subset of 60% experienced some tumor shrinkage, with partial responses and stabilization observed in 13% and 87% respectively, by central assessment. SDH-deficient GIST showed better clinical outcome than other KP-wtGIST. Conclusions: Regorafenib activity in KP-wtGIST compares favorably with other tyrosine kinase inhibitors, especially in the SDH-deficient GIST subset and it should be taken into consideration as upfront therapy of advanced KP-wtGIST. Trial registration: ClinicalTrials.gov Identifier: NCT02638766, GEIS, Bayer and SELNET. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nº. 825806
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic

  • Martín-Broto, Javier
  • Hindi, Nadia
  • Aguiar, Samuel
  • Badilla‐González, Ronald
  • Castro‐Oliden, Victor
  • Chacón, Matias
  • Correa‐Generoso, Raquel
  • Álava, Enrique de
  • Donati, Davide María
  • Eriksson, Mikael
  • Falla‐Jimenez, Martin
  • German, Gisela
  • Gobo Silva, Maria Leticia
  • Gouin, Francois
  • Gronchi, Alesandro
  • Haro‐Varas, Juan Carlos
  • Jiménez‐Brenes, Natalia
  • Kasper, Bernd
  • Lopes de Mello, Celso Abdon
  • Maki, Robert
  • Martínez-Delgado, Paula
  • Martínez‐Said, Héctor
  • Martinez‐Tlahuel, Jorge Luis
  • Morales‐Pérez, José Manuel
  • Muñoz‐Casares, Francisco Cristobal
  • Nakagawa, Suely A.
  • Ortiz‐Cruz, Eduardo Jose
  • Palmerini, Emanuela
  • Patel, Shreyaskumar
  • Moura, David S.
  • Stacchiotti, Silvia
  • Sunyach, Marie Pierre
  • Valverde, Claudia M.
  • Waisberg, Federico
  • Blay, Jean-Yves
This article also appears in: COVID-19 and Cancer Article Collection., [Background] The COVID‐19 outbreak has resulted in collision between patients infected with SARS‐CoV‐2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID‐19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. The Sarcoma European‐Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID‐19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID‐19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower‐priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology‐Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID‐19 outbreak., [Material and Methods] A total of 125 recommendations were proposed in soft‐tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2–3 months, respectively. The consensus level for each recommendation was classified as “strongly recommended” (SR) if more than 90% of experts agreed, “recommended” (R) if 75%–90% of experts agreed and “no consensus” (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European‐Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology‐Magnitude of clinical benefit scale was applied to systemic‐treatment recommendations to support prioritization., [Results] There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher‐priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower‐priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively)., [Conclusion] The consensus on 115 of 125 recommendations indicates a high‐level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID‐19 outbreak. Implications for Practice, The authors would like to thank the SELNET project. SELNET has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825806.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A comprehensive review on solitary fibrous tumor: New insights for new horizons

  • Martín-Broto, Javier
  • Mondaza-Hernández, José L.
  • Moura, David S.
  • Hindi, Nadia
[Simple Summary] Solitary fibrous tumor (SFT) is a malignant condition that exhibits different clinical behaviors ranging from low to high aggressive SFT, with dedifferentiated SFT (DD-SFT) being the fastest-growing subtype. Even when surgery alone provides curation rates above 60%, recurrences do occur in a fraction of patients where surgery is unable to provide disease control. Among the systemic therapeutic options, antiangiogenic compounds have shown higher efficacy than chemotherapy by indirect comparisons. Furthermore, rotating different antiangiogenics, at the progression time, has been shown to be effective. The exception is DD-SFT since it is resistant to antiangiogenics but can respond to chemotherapy. This comprehensive review also analyzes the underlying molecular components that play a key role in SFT origin and aggressiveness. The discovery in 2013 of anomalous fusion genes between NAB2 and STAT6 was determinant to increase the knowledge on the molecular drivers in SFT that could be potential targets for future therapies., Solitary fibrous tumor (SFT) is a rare mesenchymal, ubiquitous tumor, with an incidence of 1 new case/million people/year. In the 2020 WHO classification, risk stratification models were recommended as a better tool to determine prognosis in SFT, to the detriment of “typical” or “malignant” classic terms. The risk for metastasis is up to 35–45%, or even greater, in series with a longer follow-up. Over the last few decades, advances in immunohistochemistry and molecular diagnostics identified STAT6 nuclear protein expression and the NAB2–STAT6 fusion gene as more precise tools for SFT diagnosis. Recent evidence taken from retrospective series and from two prospective phase II clinical trials showed that antiangiogenics are active and their sequential use from first line should be considered, except for dedifferentiated SFT for which chemotherapy is the best option. Since the fusion transcript driver’s first description in 2013, new insights have been brought on key molecular events in SFT. This comprehensive review mainly focuses on the superior efficacy of antiangiogenics over chemotherapeutic agents in SFT, provides the current knowledge of key molecules that could co-drive the SFT behavior, and suggests new target candidates that deserve to be explored in preclinical and clinical research in SFT., The authors would also like to thank the SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 825806. Furthermore, the authors would like to thank the Instituto de Salud Carlos III (ISCIII)—Fondo Europeo de Desarrollo Regional (FEDER), project reference PI18/01728. David S. Moura is the recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). José L. Mondaza-Hernandez is the recipient of a PFIS predoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (FI19/00184).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ISG15 as a prognostic biomarker in solitary fibrous tumour

  • Mondaza-Hernández, José L.
  • Moura, David S.
  • López-Álvarez, María
  • Sánchez-Bustos, Paloma
  • Blanco-Alcaina, Elena
  • Castilla, Carolina
  • Collini, Paola
  • Merino-García, Jose
  • Zamora, Jorge
  • Carrillo-García, Jaime
  • Maestro, Roberta
  • Hindi, Nadia
  • García-Foncillas, Jesús
  • Martín-Broto, Javier
[Background] Solitary fibrous tumour (SFT) is a rare mesenchymal malignancy that lacks robust prognostic and predictive biomarkers. Interferon-stimulated gene 15 (ISG15) is a ubiquitin-like modifier, associated with tumour progression, and with poor survival of SFT patients, as previous published by our group. Here, we describe the role of ISG15 in the biology of this rare tumour., [Methods] ISG15 expression was assessed by immunohistochemistry in tissue microarrays from SFT patients and tested for correlation with progression-free survival and overall survival (OS). The effects of ISG15 knockdown or induction were investigated for cancer stem cell (CSC) characteristics and for drug sensitivity in unique in vitro models of SFT., [Results] The prognostic value of ISG15 for OS was validated at protein level in malignant SFT patients, prospectively treated with pazopanib and enrolled in GEIS-32 trial. In SFT in vitro models, ISG15 knockdown lead to a decrease in the expression of CSC-related genes, including SOX2, NANOG, ALDH1A1, ABCB1 and ABCC1. Likewise, ISG15 downregulation decreased the clonogenic/ tumoursphere-forming ability of SFT cells, while enhancing apoptotic cell death after doxorubicin, pazopanib or trabectedin treatment in 3D cell cultures. The regulation of CSC-related genes by ISG15 was confirmed after inducing its expression with interferon-β1; ISG15 induction upregulated 1.28- to 451-fold the expression of CSC-associated genes., [Conclusions] ISG15 is a prognostic factor in malignant SFT, regulating the expression of CSC-related genes and CSCs maintenance. Our results suggest that ISG15 could be a novel therapeutic target in SFT, which could improve the efficacy of the currently available treatments., The project was partially funded by the Instituto de Salud Carlos III (ISCIII)–Fondo Europeo de Desarrollo Regional (FEDER), project reference PI18/01728. The project was also funded by SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825806. DSM. is the recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). JLMH is the recipient of a PFIS predoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (FI19/00184)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas

  • López-Álvarez, María
  • González-Aguilera, Cristina
  • Moura, David S.
  • Sánchez-Bustos, Paloma
  • Mondaza-Hernández, José L.
  • Martín-Ruiz, Marta
  • Renshaw, Marta
  • Ramos, Rafael
  • Castilla, Carolina
  • Blanco-Alcaina, Elena
  • Hindi, Nadia
  • Martín-Broto, Javier
Although the overall survival of advanced soft-tissue sarcoma (STS) patients has increased in recent years, the median progression-free survival is lower than 5 months, meaning that there is an unmet need in this population. Among second-line treatments for advanced STS, eribulin is an anti-microtubule agent that has been approved for liposarcoma. Here, we tested the combination of eribulin with gemcitabine in preclinical models of L-sarcoma. The effect in cell viability was measured by MTS and clonogenic assay. Cell cycle profiling was studied by flow cytometry, while apoptosis was measured by flow cytometry and Western blotting. The activity of eribulin plus gemcitabine was evaluated in in vivo patient-derived xenograft (PDX) models. In L-sarcoma cell lines, eribulin plus gemcitabine showed to be synergistic, increasing the number of hypodiploid events (increased subG1 population) and the accumulation of DNA damage. In in vivo PDX models of L-sarcomas, eribulin combined with gemcitabine was a viable scheme, delaying tumour growth after one cycle of treatment, being more effective in leiomyosarcoma. The combination of eribulin and gemcitabine was synergistic in L-sarcoma cultures and it showed to be active in in vivo studies. This combination deserves further exploration in the clinical context., Eribulin and funding was kindly provided by Eisai. The authors would also like to thank the SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825806. J. Martin-Broto, D.S. Moura and N. Hindi would like to thank the International Accelerator Award funded by Cancer Research UK [C56167/A29363]. DSM is the recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). JLMH is the recipient of a PFIS predoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (FI19/00184). The authors thank HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for the processing and staining of PDX samples used in this study., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

  • Martín-Broto, Javier
  • Martínez-García, Jerónimo
  • Moura, David S.
  • Redondo, Andrés
  • Gutiérrez, Antonio
  • López-Pousa, Antonio
  • Martínez-Trufero, Javier
  • Sevilla, Isabel
  • Diaz-Beveridge, Roberto
  • Solis-Hernandez, Mª Pilar
  • Carnero, Amancio
  • Pérez, Marco
  • Marcilla, David
  • García-Foncillas, Jesús
  • Romero, Pablo
  • Fernández-Jara, Javier
  • López-López, Daniel
  • Arribas, Iván
  • Hindi, Nadia
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors demonstrated activity in terms of progression-free survival (PFS) in advanced dedifferentiated liposarcoma (DD-LPS), a sarcoma with CDK4 amplification. CDK4 overexpression is by far more common than amplification in sarcomas and it might be a rational target for CDK inhibitors. Preclinical investigators of this study found that CDK4 overexpression, while not of CDKN2A, was the most consistent predictive factor for palbociclib efficacy in sarcomas. Advanced adult-type soft-tissue sarcoma, excluding DD-LPS, or bone sarcoma patients, progressing after at least one systemic line, whose tumors overexpressed CDK4, but not CDKN2A at baseline biopsy, were accrued in this single-arm phase II trial (EudraCT number: 2016-004039-19). With the main endpoint of a 6-month PFS rate, 40% was considered promising in this population. Palbociclib was administered orally at 125 mg/day for 21 days in 28-day cycles. A total of 214 patients with 236 CDK4/CDKN2A determinations were assessed for prescreening, archival material (141), and screening, baseline biopsy (95). There were 28 (29%) with favorable mRNA profiles from 95 screened patients at baseline. From 23 enrolled patients, 21 evaluable, the 6-month PFS rate was 29% (95% CI 9–48), and there were 6 patients out of 21 with a PFS longer than 6 months. The median PFS and overall survival were 4.2 (95% CI 3.6–4.8) and 12 (95% CI 8.7–15.4) months, respectively. Translational research showed a significant correlation between CDK4 mRNA and protein expression. Palbociclib was active in a variety of sarcoma subtypes, selected by CDK4/CDKN2A, and deserves further investigation in the sarcoma context., The authors also thank the donors and all the hospitals for participating in patient screening/pre-screening. The authors would like to thank the Spanish Group for Research on Sarcomas (GEIS) for supporting the study Pfizer for providing drug supply and funding for patient screening, and the International Accelerator Award funded by Cancer Research UK [C56167/A29363], Associazione Italiana per la Ricerca sul Cancro [AIRC-24297] and Fundacion Científica—Asociacion Espanola Contra el Cancer [Foundation AECC-GEACC19007MA] for funding translational research. The authors would like to thank Patricio Ledesma, Araceli Rodriguez Morales, and Gabriela Golab for Data Management, Helen Wright for the English edition, and Paloma Sanchez-Bustos and Angela Gavilan for helping with patient screening. David S. Moura is a recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). The authors would also like to thank the SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825806. The authors would like to give special thanks to all the patients who participated in the study and their relatives., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

Supplementary Materials for Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A

  • Martín-Broto, Javier
  • Martínez-García, Jerónimo
  • Moura, David S.
  • Redondo, Andrés
  • Gutiérrez, Antonio
  • López-Pousa, Antonio
  • Martínez-Trufero, Javier
  • Sevilla, Isabel
  • Diaz-Beveridge, Roberto
  • Solis-Hernandez, Mª Pilar
  • Carnero, Amancio
  • Pérez, Marco
  • Marcilla, David
  • García-Foncillas, Jesús
  • Romero, Pablo
  • Fernández-Jara, Javier
  • López-López, Daniel
  • Arribas, Iván
  • Hindi, Nadia
This file contains: Supplementary Figure 1 and 2 and Supplementary Table 1 to 4., Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors demonstrated activity in terms of progression-free survival (PFS) in advanced dedifferentiated liposarcoma (DD-LPS), a sarcoma with CDK4 amplification. CDK4 overexpression is by far more common than amplification in sarcomas and it might be a rational target for CDK inhibitors. Preclinical investigators of this study found that CDK4 overexpression, while not of CDKN2A, was the most consistent predictive factor for palbociclib efficacy in sarcomas. Advanced adult-type soft-tissue sarcoma, excluding DD-LPS, or bone sarcoma patients, progressing after at least one systemic line, whose tumors overexpressed CDK4, but not CDKN2A at baseline biopsy, were accrued in this single-arm phase II trial (EudraCT number: 2016-004039-19). With the main endpoint of a 6-month PFS rate, 40% was considered promising in this population. Palbociclib was administered orally at 125 mg/day for 21 days in 28-day cycles. A total of 214 patients with 236 CDK4/CDKN2A determinations were assessed for prescreening, archival material (141), and screening, baseline biopsy (95). There were 28 (29%) with favorable mRNA profiles from 95 screened patients at baseline. From 23 enrolled patients, 21 evaluable, the 6-month PFS rate was 29% (95% CI 9–48), and there were 6 patients out of 21 with a PFS longer than 6 months. The median PFS and overall survival were 4.2 (95% CI 3.6–4.8) and 12 (95% CI 8.7–15.4) months, respectively. Translational research showed a significant correlation between CDK4 mRNA and protein expression. Palbociclib was active in a variety of sarcoma subtypes, selected by CDK4/CDKN2A, and deserves further investigation in the sarcoma context., The authors also thank the donors and all the hospitals for participating in patient screening/pre-screening. The authors would like to thank the Spanish Group for Research on Sarcomas (GEIS) for supporting the study Pfizer for providing drug supply and funding for patient screening, and the International Accelerator Award funded by Cancer Research UK [C56167/A29363], Associazione Italiana per la Ricerca sul Cancro [AIRC-24297] and Fundacion Científica—Asociacion Espanola Contra el Cancer [Foundation AECC-GEACC19007MA] for funding translational research. The authors would like to thank Patricio Ledesma, Araceli Rodriguez Morales, and Gabriela Golab for Data Management, Helen Wright for the English edition, and Paloma Sanchez-Bustos and Angela Gavilan for helping with patient screening. David S. Moura is a recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). The authors would also like to thank the SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825806. The authors would like to give special thanks to all the patients who participated in the study and their relatives., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression

  • Hindi, Nadia
  • Carrillo-García, Jaime
  • Blanco-Alcaina, Elena
  • Renshaw, Marta
  • Luna, Pablo
  • Durán, José
  • Jiménez, Natalia
  • Sancho, Pilar
  • Ramos, Rafael
  • Moura, David S.
  • Martín-Broto, Javier
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Rhabdomyosarcoma (RMS) in adults is a rare and aggressive disease, which lacks standard therapies for relapsed or advanced disease. This retrospective study aimed to describe the activity of BOMP-EPI (bleomycin, vincristine, methotrexate and cisplatin alternating with etoposide, cisplatin and ifosfamide), an alternative platinum-based regimen, in adult patients with relapsed/metastatic RMS. In the study, 10 patients with RMS with a median age at diagnosis of 20.8 years and a female/male distribution of 6/4 received a mean of 2.5 cycles of BOMP-EPI. The best RECIST response was a complete response in 1/10 (10%) patients, a partial response in 5/10 (50%), stable disease in 3/10 (30%) and progression in 1/10 (10%). With a median follow-up in the alive patients from the start of therapy of 30.5 months (15.7–258), all patients progressed with a median progression-free survival of 8.47 months (95% CI 8.1–8.8), and 7/10 patients died with a median overall survival of 24.7 months (95% CI 13.7–35.6). BOMP-EPI was an active chemotherapy regimen in adults with pediatric-type metastatic RMS, with outcomes in terms of survival that seem superior to what was expected for this poor-prognosis population. Low HMGB1 expression level was identified as a predictive factor of better response to this treatment., The authors thank the Instituto de Salud Carlos III (ISCIII)–Fondo Europeo de Desarrollo Regional (FEDER), project reference PI18/01728. The authors also thank the European Union’s Horizon 2020 research and innovation program, SELNET project No. 825806., This research was funded by IVAN PEREZ grant, GEIS number: GEISBECA2018. D.S.M. received a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial

  • Moura, David S.
  • López-Marti, Jesús M.
  • Benesova, Iva
  • Andrea, Carlos de
  • di Lernia, Davide
  • Lacerenza, Serena
  • Mondaza-Hernández, Jose L.
  • Martin-Ruiz, Marta
  • Ramirez-Calvo, Marta
  • Grignani, Giovanni
  • Martinez-Trufero, Javier
  • Redondo, Andres
  • Valverde, Claudia
  • Stacchiotti, Silvia
  • Lopez-Pousa, Antonio
  • Lopez-Guerrero, José A.
  • Cea Gutiérrez, Antonio
  • Encinas-Tobajas, Victor
  • Hindi, Nadia
  • Sangiolo, Dario
  • López-Martín, José A.
  • Strizova, Zuzana Ozaniak
  • Martin-Broto, Javier
Purpose: The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial. Experimental Design: Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline and week 13. Formalin-fixed paraffin-embedded samples were used for transcriptomics and multiplex immunofluorescence, whereas peripheral blood samples were used for multiplexed immunoassays. Flow cytometry and Luminex assays were performed to validate translational findings in tumor-isolated cells and peripheral blood mononuclear cells derived from patients. Results: The density of intratumoral CD8+ T cells, measured by multiplexed immunophenotyping, was significantly increased after treatment. This augment was accompanied by the dynamic significant increase in the gene expressions of CD86, CHI3L1, CXCL10, CXCL9, LAG3, and VCAM1 and the decrease in the expression levels of NR4A1. In peripheral blood, 12 proteins were significantly modulated by treatment at week 13. A score integrating the dynamic expression of the 7 genes and the 12 soluble factors separated 2 groups with distinct progression-free survival (PFS): 4.1 months [95% confidence interval, 3.5–not reached (NR)] versus 17 months (95% confidence interval, 12.0–NR), P = 0.014. This molecular score was predictive of PFS when applied to the normalized data determined in the baseline samples. Conclusions: Treatment with sunitinib and nivolumab inflamed the sarcoma microenvironment, increasing CD8+ T-cell density and the expression of several genes/proteins with relevance in the response to PD1 inhibitors. A molecular signature identified two groups of patients with distinct PFS for the combination of antiangiogenics plus PD1 inhibitor therapy., The authors would like to thank Patricio Ledesma for Data Management. The authors would like to thank the Sarcoma Foundation of America, Asociación Iker, and the Spanish Group for Research on Sarcomas (GEIS) for supporting this study. D.S. Moura was the recipient of a Sara Borrell postdoctoral fellowship funded by the NIHealth Carlos III (ISCIII; CD20/00155). The authors also thank the SELNET Project. SELNET received funding from the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 825806. The authors would like to thank Charles University, project GA UK No. 94323, and the Ministry of Health, Czech Republic, project AZV NU23J-08-00031, for supporting the study. The authors would like to thank Bristol Myers Squibb and Pfizer for allowing execution of the IMMUNOSARC trial. The authors also thank the huge effort from the patients, who accepted the collection of mandatory biopsies and peripheral blood samples., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

  • Valverde Morales, Claudia Maria
  • Morales, Jose Manuel
  • Moura, David
  • Redondo Sanchez, Andres
  • Lopez Pousa, Antonio
  • Martin-Broto, Javier
Desmoid tumors; Phase II trial; Paclitaxel, Tumores desmoides; Ensayo de fase II; Paclitaxel, Tumors desmoides; Assaig de fase II; Paclitaxel, Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best response and BPI, variation of physical function, and analgesic consumption were secondary endpoints. The translational research reported was not a pre-specified secondary outcome. Forty eligible patients started therapy, being 35 radiologically and clinically evaluable. The study achieved its primary endpoint, as 7(20%) patients obtained RECIST partial response, whereas 31(89%) experienced pain reduction of ≥2 points in BPI-SF worst pain. Therapy was well tolerated. With a median follow-up of 30(14–44) months, median 12 and 24-months PFS rates were 91%(CI 95%, 82–100) and 84%(CI 95%, 71–97). For clinical progression, 12 and 24-months PFS rates were 85% (CI 95%, 73–97) and 74% (CI 95%, 58–90) respectively. Short course of nab-paclitaxel is active, safe and achieves quick and durable responses in progressing/symptomatic DF patients., The authors would like to thank the Spanish group for Research on Sarcomas (GEIS) for supporting the study and BMS/ Celgene (study ID AX-CL-GEIS-007345) for providing drug supply. The sponsor (GEIS) has been in charge of study design, data collection, analysis and manuscript writing. The authors also thank the donors and the University Hospital Virgen del Rocío for participating in patient recruitment. The authors would like to thank Araceli Rodriguez Morales and Gabriela Golab for Data Management. David S. Moura is recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). The authors would also like to thank SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825806.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

  • Valverde Morales, Claudia Maria
  • HINDI, NADIA
  • Vincenzi, Bruno
  • Martinez-Trufero, Javier
  • GRIGNANI, GIOVANNI
  • Serrano, Cesar
  • Martin-Broto, Javier
Wild type GIST; Biomarker; Clinical trial, GIST de tipo salvaje; Biomarcador; Ensayo clínico, GIST de tipus salvatge, Biomarcador; Assaig clínic, Background Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to imatinib. Underlying oncogenic mechanisms in KP-wtGIST include overexpression of HIF1α high IGFR signaling through the MAPK pathway or BRAF activating mutation, among others. As regorafenib inhibits these signaling pathways, it was hypothesized that it could be more active as upfront therapy in advanced KP-wtGIST. Methods Adult patients with advanced KP-wtGIST after central confirmation by NGS, naïve of systemic treatment for advanced disease, were included in this international phase II trial. Eligible patients received regorafenib 160 mg per day for 21 days every 28 days. The primary endpoint was disease control rate (DCR), according to RECIST 1.1 at 12 weeks by central radiological assessment. Results From May 2016 to October 2020, 30 patients were identified as KP-wtGIST by Sanger sequencing and 16 were confirmed by central molecular screening with NGS. Finally, 15 were enrolled and received regorafenib. The study was prematurely closed due to the low accrual worsened by COVID outbreak. The DCR at 12 weeks was 86.7% by central assessment. A subset of 60% experienced some tumor shrinkage, with partial responses and stabilization observed in 13% and 87% respectively, by central assessment. SDH-deficient GIST showed better clinical outcome than other KP-wtGIST. Conclusions Regorafenib activity in KP-wtGIST compares favorably with other tyrosine kinase inhibitors, especially in the SDH-deficient GIST subset and it should be taken into consideration as upfront therapy of advanced KP-wtGIST., GEIS, Bayer and SELNET. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nº. 825806.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic

  • Martín Broto, Javier|||0000-0001-7350-6916
  • Hindi, Nadia|||0000-0002-5864-762X
  • Aguiar Júnior, Samuel|||0000-0003-3476-727X
  • Badilla-González, Ronald
  • Castro-Oliden, Victor|||0000-0003-2828-7325
  • Chacón, Matias|||0000-0001-6872-4185
  • Correa Genoroso, Raquel|||0000-0002-8212-8897
  • De Álava, Enrique|||0000-0001-8400-046X
  • Donati, Davide Maria|||0000-0002-9170-0576
  • Eriksson, Mikael
  • Falla-Jimenez, Martin
  • German, Gisela
  • Gobo Silva, Maria Leticia
  • Gouin, François
  • Gronchi, Alessandro|||0000-0002-4703-3534
  • Haro-Varas, Juan|||0000-0003-0678-585X
  • Jiménez-Brenes, Natalia
  • Lopes de Mello, Celso Abdon
  • Kasper, Bernd|||0000-0001-8425-8356
  • Maki, Robert G.|||0000-0002-9853-2528
  • Martínez-Delgado, Paula
  • Martínez-Said, Hector
  • Martinez-Tlahuel, Jorge Luis
  • Morales Pérez, José Manuel
  • Muñoz-Casares, Francisco Cristobal
  • Nakagawa, Suely A.
  • Ortiz Cruz, Eduardo J.|||0000-0002-1405-0688
  • Palmerini, Emanuela|||0000-0003-3406-6705
  • Patel, Shreyaskumar|||0000-0002-0026-2348
  • Moura, David S.
  • Stacchiotti, Silvia|||0000-0002-1742-8666
  • Sunyach, Marie Pierre
  • Valverde Morales, Claudia Maria
  • Waisberg, Federico
  • Blay, Jean-Yves|||0000-0001-7190-120X
Background: The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. Material and Methods: A total of 125 recommendations were proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2-3 months, respectively. The consensus level for each recommendation was classified as "strongly recommended" (SR) if more than 90% of experts agreed, "recommended" (R) if 75%-90% of experts agreed and "no consensus" (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European-Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology-Magnitude of clinical benefit scale was applied to systemic-treatment recommendations to support prioritization. Results: There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher-priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower-priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively). Conclusion: The consensus on 115 of 125 recommendations indicates a high-level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID-19 outbreak. Implications for Practice: The Sarcoma European-Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID-19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID-19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower-priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology-Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A novel nfix-stat6 gene fusion in solitary fibrous tumor, A case report

  • Moura, David S.
  • Díaz-Martín, Juan|||0000-0002-3985-6434
  • Bagué Rosell, Sílvia|||0000-0001-9980-7231
  • Orellana Fernández, Ruth|||0000-0003-1260-7064
  • Sebio, Ana|||0000-0003-3333-2370
  • Mondaza Hernandez, Jose Lucinio|||0000-0002-5642-3796
  • Salguero-Aranda, Carmen
  • Rojo, Federico|||0000-0001-9989-0290
  • Hindi, Nadia|||0000-0002-5864-762X
  • Fletcher, Christopher D.M.
  • Martín Broto, Javier|||0000-0001-7350-6916
Solitary fibrous tumor is a rare subtype of soft-tissue sarcoma with a wide spectrum of histopathological features and clinical behaviors, ranging from mildly to highly aggressive tumors. The defining genetic driver alteration is the gene fusion NAB2-STAT6, resulting from a paracentric inversion within chromosome 12q, and involving several different exons in each gene. STAT6 (sig-nal transducer and activator of transcription 6) nuclear immunostaining and/or the identification of NAB2-STAT6 gene fusion is required for the diagnostic confirmation of solitary fibrous tumor. In the present study, a new gene fusion consisting of Nuclear Factor I X (NFIX), mapping to 19p13.2 and STAT6, mapping to 12q13.3 was identified by targeted RNA-Seq in a 74-year-old female patient diagnosed with a deep-seated solitary fibrous tumor in the pelvis. Histopathologically, the neo-plasm did not display nuclear pleomorphism or tumor necrosis and had a low proliferative index. A total of 378 unique reads spanning the NFIXexon8-STAT6exon2 breakpoint with 55 different start sites were detected in the bioinformatic analysis, which represented 59.5% of the reads intersecting the genomic location on either side of the breakpoint. Targeted RNA-Seq results were validated by RT-PCR/ Sanger sequencing. The identification of a new gene fusion partner for STAT6 in solitary fibrous tumor opens intriguing new hypotheses to refine the role of STAT6 in the sarcomatogenesis of this entity.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

SELNET clinical practice guidelines for bone sarcoma

  • Blay, Jean-Yves|||0000-0001-7190-120X
  • Palmerini, Emanuela|||0000-0003-3406-6705
  • Bollard, Julien|||0000-0002-9378-5665
  • Aguiar Júnior, Samuel|||0000-0003-3476-727X
  • Ángel, Martín Osvaldo|||0000-0002-1463-8887
  • Araya, Beatriz|||0000-0002-7804-0518
  • Badilla-González, Ronald
  • Bernabeu, Daniel|||0000-0003-0828-9104
  • Campos, Fernando|||0000-0002-7771-8059
  • Caro-Sanchez, Claudia Haydee Sarai
  • Carvajal Montoya, A.
  • Casavilca-Zambrano, Sandro|||0000-0001-8406-739X
  • Castro-Oliden, Victor|||0000-0003-2828-7325
  • Chacón, Matias|||0000-0001-6872-4185
  • Clara-Altamirano, Miguel Ángel
  • Collini, Paola|||0000-0002-6158-210X
  • Correa Genoroso, Raquel|||0000-0002-8212-8897
  • Costa, Felipe D.
  • Cuellar, M.
  • Dei Tos, Angelo|||0000-0002-1228-8940
  • Domínguez Malagón, Hugo Ricardo
  • Donati, Davide Maria|||0000-0002-9170-0576
  • Dufresne, Armelle
  • Eriksson, Mikael
  • Farias-Loza, M.
  • Frezza, Anna Maria|||0000-0003-2335-7224
  • Frisoni, Tommaso|||0000-0001-6109-3202
  • Garcia-Ortega, Dorian Yarih|||0000-0002-1302-2896
  • Gelderblom, Hans J.|||0000-0001-9270-8636
  • Gouin, François
  • Gómez-Mateo, María Carmen
  • Gronchi, Alessandro|||0000-0002-4703-3534
  • Haro-Varas, Juan|||0000-0003-0678-585X
  • Hindi, Nadia|||0000-0002-5864-762X
  • Huanca, Lourdes
  • Jimenez, Natalia|||0000-0002-7735-2341
  • Karanian, Marie
  • Kasper, Bernd|||0000-0001-8425-8356
  • Lopes, Artur
  • Lopes David, B.B.
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Lutter, Guido
  • Maki, Robert G.|||0000-0002-9853-2528
  • Martinez-Said, Héctor|||0000-0002-9881-4592
  • Martinez-Tlahuel, Jorge Luis
  • Mello, Celso A.|||0000-0002-8315-1562
  • Morales Pérez, José Manuel
  • Moura, David S.
  • Nakagawa, Suely Akiko
  • Nascimento, Antônio Geraldo
  • Ortiz Cruz, Eduardo J.|||0000-0002-1405-0688
  • Patel, Shreyaskumar|||0000-0002-0026-2348
  • Pfluger, Yanina
  • Provenzano, Salvatore|||0000-0003-0425-4692
  • Righi, Alberto
  • Rodriguez, Andrés
  • Santos, Telma G.
  • Scotlandi, Katia|||0000-0001-6114-9499
  • MLG, Silva
  • Soulé, Tomás
  • Stacchiotti, Silvia|||0000-0002-1742-8666
  • Valverde Morales, Claudia Maria
  • Waisberg, Federico Daniel|||0000-0003-4435-5068
  • Zamora Estrada, Esteban
  • Martín Broto, Javier|||0000-0001-7350-6916
Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

SELNET clinical practice guidelines for soft tissue sarcoma and GIST

  • Blay, Jean-Yves|||0000-0001-7190-120X
  • Hindi, Nadia|||0000-0002-5864-762X
  • Bollard, Julien|||0000-0002-9378-5665
  • Aguiar Júnior, Samuel|||0000-0003-3476-727X
  • Ángel, Martín Osvaldo|||0000-0002-1463-8887
  • Araya, Beatriz|||0000-0002-7804-0518
  • Badilla-González, Ronald
  • Bernabeu, Daniel|||0000-0003-0828-9104
  • Campos, Fernando|||0000-0002-7771-8059
  • Caro-Sánchez, C.H.S.
  • Carvajal, B.
  • Carvajal Montoya, A.
  • Casavilca-Zambrano, Sandro|||0000-0001-8406-739X
  • Castro-Oliden, Victor|||0000-0003-2828-7325
  • Chacón, Matias|||0000-0001-6872-4185
  • Clara-Altamirano, Miguel Ángel
  • Collini, Paola|||0000-0002-6158-210X
  • Correa Genoroso, Raquel|||0000-0002-8212-8897
  • Costa, Felipe D.
  • Cuellar, M.
  • Dei Tos, Angelo|||0000-0002-1228-8940
  • Dominguez Malagón, Hugo Ricardo
  • Donati, Davide Maria|||0000-0002-9170-0576
  • Dufresne, Armelle
  • Eriksson, Mikael
  • Farias-Loza, M.
  • Fernandez, Piga|||0000-0002-7846-146X
  • Frezza, Anna Maria|||0000-0003-2335-7224
  • Frisoni, Tommaso|||0000-0001-6109-3202
  • Garcia-Ortega, Dorian Yarih|||0000-0002-1302-2896
  • Gelderblom, Hans J.|||0000-0001-9270-8636
  • Gouin, François
  • Gómez-Mateo, María Carmen
  • Gronchi, Alessandro|||0000-0002-4703-3534
  • Haro-Varas, Juan|||0000-0003-0678-585X
  • Huanca, Lourdes
  • Jimenez, Natalia|||0000-0002-7735-2341
  • Karanian, Marie
  • Kasper, Bernd|||0000-0001-8425-8356
  • Lopes David, B.B.
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Lutter, Guido
  • Martinez-Said, Héctor|||0000-0002-9881-4592
  • Martinez-Tlahuel, Jorge Luis
  • Mello, Celso A.|||0000-0002-8315-1562
  • Morales Pérez, José Manuel
  • Moura, David S.
  • Nascimento, Antônio Geraldo
  • Ortiz Cruz, Eduardo J.|||0000-0002-1405-0688
  • Palmerini, Emanuela|||0000-0003-3406-6705
  • Patel, Shreyaskumar|||0000-0002-0026-2348
  • Pfluger, Yanina
  • Provenzano, Salvatore|||0000-0003-0425-4692
  • Righi, Alberto
  • Rodriguez, Andrés
  • Salas, Rodrigo
  • Santos, Telma G.
  • Scotlandi, Katia|||0000-0001-6114-9499
  • Soulé, Tomás
  • Stacchiotti, Silvia|||0000-0002-1742-8666
  • Valverde Morales, Claudia Maria
  • Waisberg, Federico Daniel|||0000-0003-4435-5068
  • Zamora Estrada, Esteban
  • Martín Broto, Javier|||0000-0001-7350-6916
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

  • Hidalgo-Ríos, Samuel
  • Carrillo García, Jaime|||0000-0002-2861-3015
  • Moura, David S.
  • Stacchiotti, Silvia|||0000-0002-1742-8666
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Italiano, Antoine|||0000-0002-8540-5351
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Grignani, Giovanni|||0000-0001-5515-569X
  • Hindi, Nadia|||0000-0002-5864-762X
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Palmerini, Emanuela|||0000-0003-3406-6705
  • Sebio, Ana|||0000-0003-3333-2370
  • Bernabeu, Daniel|||0000-0003-0828-9104
  • Le Cesne, Axel
  • Casali, Paolo Giovanni|||0000-0003-4056-8023
  • Blay, Jean-Yves|||0000-0001-7190-120X
  • Cruz-Jurado, Josefina|||0000-0001-6398-1641
  • Martín Broto, Javier|||0000-0001-7350-6916
Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16.8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

  • Martín Broto, Javier|||0000-0001-7350-6916
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Moura, David S.
  • Valverde Morales, Claudia Maria
  • Morales, Jose Manuel
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Diaz-Beveridge, Roberto|||0000-0003-3719-7014
  • Luna, Pablo
  • Martínez Marín, Virginia
  • Marcilla, David
  • Arribas, Ivan|||0000-0001-7600-8066
  • Ledesma, Patricio
  • Lopez-Martin, Jose A.|||0000-0001-7530-3207
  • Di Lernia, Davide
  • Zamora, Jorge
  • Hindi, Nadia|||0000-0002-5864-762X
Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best response and BPI, variation of physical function, and analgesic consumption were secondary endpoints. The translational research reported was not a pre-specified secondary outcome. Forty eligible patients started therapy, being 35 radiologically and clinically evaluable. The study achieved its primary endpoint, as 7(20%) patients obtained RECIST partial response, whereas 31(89%) experienced pain reduction of ≥2 points in BPI-SF worst pain. Therapy was well tolerated. With a median follow-up of 30(14-44) months, median 12 and 24-months PFS rates were 91%(CI 95%, 82-100) and 84%(CI 95%, 71-97). For clinical progression, 12 and 24-months PFS rates were 85% (CI 95%, 73-97) and 74% (CI 95%, 58-90) respectively. Short course of nab-paclitaxel is active, safe and achieves quick and durable responses in progressing/symptomatic DF patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

  • Martín Broto, Javier|||0000-0001-7350-6916
  • Martinez-Garcia, Jeronimo
  • Moura, David S.
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Sevilla, Isabel
  • Diaz-Beveridge, Roberto|||0000-0003-3719-7014
  • Solis-Hernandez, Maria Pilar
  • Carnero, Amancio|||0000-0003-4357-3979
  • Perez, Marco
  • Marcilla, David
  • Garcia-Foncillas, Jesus
  • Romero, Pablo
  • Fernandez-Jara, Javier
  • López López, Daniel|||0000-0001-7672-7335
  • Arribas, Ivan|||0000-0001-7600-8066
  • Hindi, Nadia|||0000-0002-5864-762X
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors demonstrated activity in terms of progression-free survival (PFS) in advanced dedifferentiated liposarcoma (DD-LPS), a sarcoma with CDK4 amplification. CDK4 overexpression is by far more common than amplification in sarcomas and it might be a rational target for CDK inhibitors. Preclinical investigators of this study found that CDK4 overexpression, while not of CDKN2A, was the most consistent predictive factor for palbociclib efficacy in sarcomas. Advanced adult-type soft-tissue sarcoma, excluding DD-LPS, or bone sarcoma patients, progressing after at least one systemic line, whose tumors overexpressed CDK4, but not CDKN2A at baseline biopsy, were accrued in this single-arm phase II trial (EudraCT number: 2016-004039-19). With the main endpoint of a 6-month PFS rate, 40% was considered promising in this population. Palbociclib was administered orally at 125 mg/day for 21 days in 28-day cycles. A total of 214 patients with 236 CDK4/CDKN2A determinations were assessed for prescreening, archival material (141), and screening, baseline biopsy (95). There were 28 (29%) with favorable mRNA profiles from 95 screened patients at baseline. From 23 enrolled patients, 21 evaluable, the 6-month PFS rate was 29% (95% CI 9-48), and there were 6 patients out of 21 with a PFS longer than 6 months. The median PFS and overall survival were 4.2 (95% CI 3.6-4.8) and 12 (95% CI 8.7-15.4) months, respectively. Translational research showed a significant correlation between CDK4 mRNA and protein expression. Palbociclib was active in a variety of sarcoma subtypes, selected by CDK4/CDKN2A, and deserves further investigation in the sarcoma context.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

REGISTRI, Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

  • Martín Broto, Javier|||0000-0001-7350-6916
  • Valverde Morales, Claudia Maria
  • Hindi, Nadia|||0000-0002-5864-762X
  • Vincenzi, Bruno
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Grignani, Giovanni|||0000-0001-5515-569X
  • Italiano, Antoine|||0000-0002-8540-5351
  • Lavernia, Javier
  • Vallejo, Ana
  • Tos, Paolo Dei
  • Le Loarer, Francois
  • Gonzalez-Campora, Ricardo
  • Ramos, Rafel|||0000-0001-7970-5537
  • Hernández-Jover, Diana
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Serrano, Cesar|||0000-0003-1416-8739
  • Monteagudo, Maria
  • Letón, Rocio
  • Robledo, Mercedes|||0000-0001-6256-5902
  • Moura, David S.
  • Martin-Ruiz, Marta
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Cruz, Julia
  • Fernandez-Serra, Antonio
  • Blay, Jean-Yves|||0000-0001-7190-120X
  • Fumagalli, Elena
  • Martínez Marín, Virginia
Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to imatinib. Underlying oncogenic mechanisms in KP-wtGIST include overexpression of HIF1α high IGFR signaling through the MAPK pathway or BRAF activating mutation, among others. As regorafenib inhibits these signaling pathways, it was hypothesized that it could be more active as upfront therapy in advanced KP-wtGIST. Adult patients with advanced KP-wtGIST after central confirmation by NGS, naïve of systemic treatment for advanced disease, were included in this international phase II trial. Eligible patients received regorafenib 160 mg per day for 21 days every 28 days. The primary endpoint was disease control rate (DCR), according to RECIST 1.1 at 12 weeks by central radiological assessment. From May 2016 to October 2020, 30 patients were identified as KP-wtGIST by Sanger sequencing and 16 were confirmed by central molecular screening with NGS. Finally, 15 were enrolled and received regorafenib. The study was prematurely closed due to the low accrual worsened by COVID outbreak. The DCR at 12 weeks was 86.7% by central assessment. A subset of 60% experienced some tumor shrinkage, with partial responses and stabilization observed in 13% and 87% respectively, by central assessment. SDH-deficient GIST showed better clinical outcome than other KP-wtGIST. Regorafenib activity in KP-wtGIST compares favorably with other tyrosine kinase inhibitors, especially in the SDH-deficient GIST subset and it should be taken into consideration as upfront therapy of advanced KP-wtGIST. ClinicalTrials.gov Identifier: NCT02638766. The online version contains supplementary material available at 10.1186/s12943-023-01832-9.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS), A Spanish Group for Research on Sarcomas (GEIS) study

  • Moura, David S.
  • Mondaza-Hernandez, Jose L.
  • Sanchez-Bustos, Paloma
  • Peña-Chilet, Maria
  • Cordero Varela, Juan Antonio|||0000-0002-7373-5433
  • Lopez-Alvarez, Maria
  • Carrillo-Garcia, Jaime
  • Martin-Ruiz, Marta
  • Romero-Gonzalez, Pablo
  • Renshaw-Calderon, Marta
  • Ramos, Rafel|||0000-0001-7970-5537
  • Marcilla, David
  • Alvarez-Alegret, Ramiro
  • Agra Pujol, Carolina|||0000-0003-4843-5786
  • Izquierdo, Francisco
  • Ortega-Medina, Luis
  • Martin-Davila, Francisco
  • Hernandez-Leon, Carmen Nieves
  • Romagosa Perez Portabella, Maria Cleofe|||0000-0002-9478-7320
  • Salgado, Maria Angeles Vaz
  • Lavernia, Javier
  • Bagué Rosell, Sílvia|||0000-0001-9980-7231
  • Mayodormo-Aranda, Empar
  • Alvarez, Rosa|||0000-0003-0935-8298
  • Valverde Morales, Claudia Maria
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Castilla-Ramirez, Carolina
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Hindi, Nadia|||0000-0002-5864-762X
  • Garcia-Foncillas, Jesus
  • Martín Broto, Javier|||0000-0001-7350-6916
HMGA1 is a structural epigenetic chromatin factor that has been associated with tumor progression and drug resistance. Here, we reported the prognostic/predictive value of HMGA1 for trabectedin in advanced soft-tissue sarcoma (STS) and the effect of inhibiting HMGA1 or the mTOR downstream pathway in trabectedin activity. The prognostic/predictive value of HMGA1 expression was assessed in a cohort of 301 STS patients at mRNA (n = 133) and protein level (n = 272), by HTG EdgeSeq transcriptomics and immunohistochemistry, respectively. The effect of HMGA1 silencing on trabectedin activity and gene expression profiling was measured in leiomyosarcoma cells. The effect of combining mTOR inhibitors with trabectedin was assessed on cell viability in vitro studies, whereas in vivo studies tested the activity of this combination. HMGA1 mRNA and protein expression were significantly associated with worse progression-free survival of trabectedin and worse overall survival in STS. HMGA1 silencing sensitized leiomyosarcoma cells for trabectedin treatment, reducing the spheroid area and increasing cell death. The downregulation of HGMA1 significantly decreased the enrichment of some specific gene sets, including the PI3K/AKT/mTOR pathway. The inhibition of mTOR, sensitized leiomyosarcoma cultures for trabectedin treatment, increasing cell death. In in vivo studies, the combination of rapamycin with trabectedin downregulated HMGA1 expression and stabilized tumor growth of 3-methylcholantrene-induced sarcoma-like models. HMGA1 is an adverse prognostic factor for trabectedin treatment in advanced STS. HMGA1 silencing increases trabectedin efficacy, in part by modulating the mTOR signaling pathway. Trabectedin plus mTOR inhibitors are active in preclinical models of sarcoma, downregulating HMGA1 expression levels and stabilizing tumor growth.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

  • Valverde Morales, Claudia Maria
  • Morales, Jose Manuel
  • Moura, David
  • Redondo Sanchez, Andres
  • Lopez Pousa, Antonio
  • Martin-Broto, Javier
Desmoid tumors; Phase II trial; Paclitaxel, Tumores desmoides; Ensayo de fase II; Paclitaxel, Tumors desmoides; Assaig de fase II; Paclitaxel, Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best response and BPI, variation of physical function, and analgesic consumption were secondary endpoints. The translational research reported was not a pre-specified secondary outcome. Forty eligible patients started therapy, being 35 radiologically and clinically evaluable. The study achieved its primary endpoint, as 7(20%) patients obtained RECIST partial response, whereas 31(89%) experienced pain reduction of ≥2 points in BPI-SF worst pain. Therapy was well tolerated. With a median follow-up of 30(14–44) months, median 12 and 24-months PFS rates were 91%(CI 95%, 82–100) and 84%(CI 95%, 71–97). For clinical progression, 12 and 24-months PFS rates were 85% (CI 95%, 73–97) and 74% (CI 95%, 58–90) respectively. Short course of nab-paclitaxel is active, safe and achieves quick and durable responses in progressing/symptomatic DF patients., The authors would like to thank the Spanish group for Research on Sarcomas (GEIS) for supporting the study and BMS/ Celgene (study ID AX-CL-GEIS-007345) for providing drug supply. The sponsor (GEIS) has been in charge of study design, data collection, analysis and manuscript writing. The authors also thank the donors and the University Hospital Virgen del Rocío for participating in patient recruitment. The authors would like to thank Araceli Rodriguez Morales and Gabriela Golab for Data Management. David S. Moura is recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). The authors would also like to thank SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825806.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

  • Valverde Morales, Claudia Maria
  • HINDI, NADIA
  • Vincenzi, Bruno
  • Martinez-Trufero, Javier
  • GRIGNANI, GIOVANNI
  • Serrano, Cesar
  • Martin-Broto, Javier
Wild type GIST; Biomarker; Clinical trial, GIST de tipo salvaje; Biomarcador; Ensayo clínico, GIST de tipus salvatge, Biomarcador; Assaig clínic, Background Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to imatinib. Underlying oncogenic mechanisms in KP-wtGIST include overexpression of HIF1α high IGFR signaling through the MAPK pathway or BRAF activating mutation, among others. As regorafenib inhibits these signaling pathways, it was hypothesized that it could be more active as upfront therapy in advanced KP-wtGIST. Methods Adult patients with advanced KP-wtGIST after central confirmation by NGS, naïve of systemic treatment for advanced disease, were included in this international phase II trial. Eligible patients received regorafenib 160 mg per day for 21 days every 28 days. The primary endpoint was disease control rate (DCR), according to RECIST 1.1 at 12 weeks by central radiological assessment. Results From May 2016 to October 2020, 30 patients were identified as KP-wtGIST by Sanger sequencing and 16 were confirmed by central molecular screening with NGS. Finally, 15 were enrolled and received regorafenib. The study was prematurely closed due to the low accrual worsened by COVID outbreak. The DCR at 12 weeks was 86.7% by central assessment. A subset of 60% experienced some tumor shrinkage, with partial responses and stabilization observed in 13% and 87% respectively, by central assessment. SDH-deficient GIST showed better clinical outcome than other KP-wtGIST. Conclusions Regorafenib activity in KP-wtGIST compares favorably with other tyrosine kinase inhibitors, especially in the SDH-deficient GIST subset and it should be taken into consideration as upfront therapy of advanced KP-wtGIST., GEIS, Bayer and SELNET. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nº. 825806.